Febuxostat and Cardiovascular Events: A Systematic Review and Meta-Analysis

BACKGROUND: Febuxostat is approved in the United States for the management of hyperuricemia in patients with gout. In November 2017 the FDA released a warning alert on a possible link between febuxostat and cardiovascular disease (CVD) reported in a single clinical trial. OBJECTIVE: To conduct a sys...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Int J Rheumatol
Egile Nagusiak: Cuenca, John A., Balda, Javier, Palacio, Ana, Young, Larry, Pillinger, Michael H., Tamariz, Leonardo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Hindawi 2019
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6378016/
https://ncbi.nlm.nih.gov/pubmed/30863448
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/1076189
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak